-
The pharmacokinetic interaction of lopinavir/ritonavir and amprenavir in
clinical practice
HE Reynolds, SE Gibbons, J Tjia, et al
Abstract-
Efficacy of the combination of Amprenavir, Ritonavir and Efavirenz in
multiply pretreated
HIV-infected patients: Two years follow up
K Römer, B Salzberger, G Fätkenheuer, et al
Abstract
-
Efficacy and safety of amprenavir (APV)/ritonavir (RTV) 600/100mg BID
compared to
APV 1200mg BID in
ART-experienced and naïve subjects: ESS40011
J Nadler, J Gathe, R Pollard, et al
Abstract-
Decreased plasma concentrations of Amprenavir and Lopinavir in HIV
patients on this combination
T Vanig, M Brill
Abstract
-
Direct observed therapy (DOT) in HIV is it a feasible in clinical
practice? Problems associated with
DOT an amprenavir containing HAART regimen in an antiretroviral naïve,
inner-city minority patients
with poor HIV knowledge and very advanced AIDS
D Jayaweera, T Tanner, A M Nowak, et al
Abstract
-
Prospective Study of Sequencing Strategies of Protease Inhibitor Based
HAART: Salvagability of
Amprenavir (APV) with Nelfinavir (NLF) based therapies among
antiretroviral naive HIV-infected patients
initiating therapy
SR Schrader, P Rohde, J Musser, ,et al
Abstract
-
Antiviral potency and tolerability of a convenient once a day direct
observed therapy with amprenavir
containing haart regimen in an antiretroviral naïve, inner-city minority
patients with poor HIV knowledge
and very advanced AIDS
D Jayaweera, T Tanner, AM Nowak, et al
Abstract
-
A
triple protease inhibitor [PI] salvage regimen of amprenavir [APV] +
saquinavir [SQV] + minidose
ritonavir [r]: steady state [SS] pharmacokinetics [PK] and initial RNA
and CD4 response
AH Corbett, JJ Eron, M Diebold, et al
Abstract
-
Amprenavir in salvage therapy: good virological and immunological
response in a cohort of 45 patients
R Bogner, J
Eberle, U Troendle, et al
Abstract
-
Drug interaction between amprenavir and lopinavir/ritonavir in salvage
therapy
H Khanlou, E Graham, M Brill, C Farthing
Abstract -
Effective plasma levels of amprenavir in highly challenging, naive HIV
patients following a
once daily HAART regimen
V Garg, M Brill, L Beeler, et al
Abstract
-
Switch from high to low dose amprenavir in combination with efavirenz
and ritonavir
DF Alvarez-Arnao, W Pace, MJ Gold, G Boone
Abstract
-
Clinical efficacy of salvage regimens containing both amprenavir and
lopinavir/ritonavir as
compared to salvage regimens containing only lopinavir/ritonavir
stratified by NNRTI-experience
M Loutfy, C Thompson, M Trpeski, et al
Abstract
-
Efficacy of the combination of Amprenavir, Ritonavir and Efavirenz in
multiply pretreated HIV-infected
patients: Two years follow up
K Römer, B Salzberger, G Fätkenheuer
Abstract
-
Boosted dual PI Therapy: amprenavir/lopinavir/ritonavir provides
improved immunologic outcome and
maintains clinical stability in heavily pretreated patients
FG Reyes, P Chambliss, D Rusu, HA Grossman
Abstract
-
Total cholesterol and triglycerides changes in antiretroviral pretreated
HIV-patients who start
Amprenavir/ritonavir based HAART as rescue therapy
A Costa, F Pulido, R Rubio, et al
Abstract
-
Amprenavir trough concentrations in HIV patients receiving chronic
salvage therapy with amprenavir
and lopinavir
KI Klem, MJ Shelton, LD Esch, et al
Abstract
-
Predictivity of amprenavir plasma concentrations on virological response
in HIV-infected patients treated
with amprenavir/ritonavir containing regimen : a Genophar substudy
G Peytavin, C Lamotte, A G Marcelin, et al
Abstract
-
Mutations in HIV-1 protease associated with resistance to amprenavir
contribute towards phenotypic
resistance to lopinavir
NT Parkin, C Chappey, C J Petropoulos
Abstract
-
Virological response and safety of Amprenavir plus Lopinavir/Ritonavir
in heavily pre-treated patients
R Kulasegaram, S McCormick, R Shah, et al
Abstract
-
Efavirenz does not affect Amprenavir
exposure when co-administered with Ritonavir in HIV-1+ subjects
RG Hewitt, D Cloen, T Olatinwo
Abstract
-
Preliminary results of intensification therapy with amprenavir (APV)/
ritonavir (RTV) in two differents doses:
1200 (APV)/ 200 (RTV) qd vs 600 (APV)/ 100 (RTV) bid in a heavily
pretreated patients failing HAART
JL Blanco, M Sarasa, M Arnedo, et al
Abstract
|
Amprenavir Main
Page
Documents identified with this icon are in Portable Document Format (PDF)
and require the
Adobe
Acrobat Reader
